Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer (Q39131597)

9 September 2017

Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer (English)

1 reference

9 September 2017

1 reference

1 reference

Suiyang Zhou

1

1 reference

9 September 2017

Liangdan Tang

2

1 reference

9 September 2017

Haixia Wang

3

1 reference

9 September 2017

Jiemin Dai

4

1 reference

9 September 2017

Jing Zhang

5

1 reference

9 September 2017

Liyuan Shen

6

1 reference

9 September 2017

Shu-Wing Ng

7

1 reference

9 September 2017

Ross S Berkowitz

8

1 reference

9 September 2017

language of work or name

English

0 references

publication date

29 June 2013

1 reference

9 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Gynecologic Oncology

1 reference

9 September 2017

131

1 reference

9 September 2017

1

1 reference

9 September 2017

69-76

1 reference

9 September 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Focus on epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Screening for ovarian cancer in the general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Mechanisms of transcoelomic metastasis in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

The BCR-ABL story: bench to bedside and back

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Abl kinases are required for invadopodia formation and chemokine-induced invasion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

ABL regulation by AXL promotes cisplatin resistance in esophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Regulation of actin dynamics by WASP family proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Regulation of actin polymerization and adhesion-dependent cell edge protrusion by the Abl-related gene (Arg) tyrosine kinase and N-WASp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Molecular layers underlying cytoskeletal remodelling during cortical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Assembly and biological role of podosomes and invadopodia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Liprin-α1 regulates breast cancer cell invasion by affecting cell motility, invadopodia and extracellular matrix degradation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.06.031

10.1016/J.YGYNO.2013.06.031

7 January 2021

Identifiers

DOI

1 reference

9 September 2017

1 reference